Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial.

Wenyan PengXiuying JiangLei ZhuXiaofeng LiQizhi ZhouYing JieZhipeng YouMiaoqin WuXiuming JinBenjamin X LiShiyou Zhou

Published in: Drug design, development and therapy (2022)

Clinically and statistically significant improvements in ICSS, tear production, and symptoms were observed in participants administered CyclAGel 0.05% QD for moderate-to-severe DED. CyclAGel 0.05% QD is a new effective, safe, and well-tolerated therapeutic option that might bring additional benefits of convenience and compliance as a once-A-day treatment for DED.

Keyphrases

phase iii
open label
double blind
clinical trial
phase ii
placebo controlled
randomized controlled trial
study protocol
early onset
combination therapy
depressive symptoms